How the immune system responds to therapeutic biological agents.

about

How the immune system responds to therapeutic biological agents.

Item

http://www.wikidata.org/entity/Q41882370

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

How the immune system responds to therapeutic biological agents.

@en

type

Item

label

How the immune system responds to therapeutic biological agents.

@en

prefLabel

How the immune system responds to therapeutic biological agents.

@en

P1476

How the immune system responds to therapeutic biological agents.

@en

P2093

Alessandra Vultaggio

http://www.w3.org/2001/XMLSchema#string

Andrea Ferraro

http://www.w3.org/2001/XMLSchema#string

Andrea Matucci

http://www.w3.org/2001/XMLSchema#string

Daniele Cammelli

http://www.w3.org/2001/XMLSchema#string

Enrico Maggi

http://www.w3.org/2001/XMLSchema#string

Francesca Nencini

http://www.w3.org/2001/XMLSchema#string

Giulia Petroni

http://www.w3.org/2001/XMLSchema#string

Sara Pratesi

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource.

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.

Factors influencing the immunogenicity of therapeutic proteins.

P304

38-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0300060515593248

http://www.w3.org/2001/XMLSchema#string

P433

1 suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27683137

http://www.w3.org/2001/XMLSchema#string

P932

5536528

http://www.w3.org/2001/XMLSchema#string